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While the human fetal immune system defaults to a program of tolerance, there is a
concurrent need for protective immunity to meet the antigenic challenges encountered after
birth. Activation of T cells in utero is associated with the fetal inflammatory response, with
broad implications for the health of the fetus and of the pregnancy. However, the
characteristics of the fetal effector T cells that contribute to this process are largely unknown.
We analyzed primary human fetal lymphoid and mucosal tissues and performed phenotypic,
functional, and transcriptional analysis to identify T cells with proinflammatory potential. The
frequency and function of fetal-specific effector T cells was assessed in the cord blood of
infants with localized and systemic inflammatory pathologies and compared with that of
healthy term controls.
We identified a transcriptionally distinct population of CD4+ T cells characterized by
expression of the transcription factor promyelocytic leukemia zinc finger (PLZF).
PLZF+CD4+ T cells were specifically enriched in the fetal intestine, possessed an effector
memory phenotype, and rapidly produced proinflammatory cytokines. Engagement of the C-
type lectin CD161 on these cells inhibited TCR-dependent production of IFN-g in a fetal-
specific manner. IFN-g–producing PLZF+CD4+ T cells […]
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Introduction
In a healthy human pregnancy, fetal immunity is uniquely adapt-
ed both to promote tolerance in utero and to subsequently provide 
protection after birth. Unlike in mice, which lack peripheral TCR-
αβ cells in utero (1), in humans, these T cells begin to populate 
peripheral organs by 11 to 14 weeks of gestation (2, 3). Fetal adap-
tive tolerance is driven in large part by the predilection of naive 
CD4+ T cells to differentiate into Tregs (4), yet less is known about 
the development of protective adaptive immunity. Activation of 
the human fetal immune system and the ensuing fetal inflamma-
tory response are associated with premature termination of preg-
nancy and severe neonatal morbidity (5, 6). Activated T cells and 
reduced suppressive Treg activity are evident during fetal inflam-
mation (7–10), and maternal-reactive fetal Th1 cells are implicated 
in the pathophysiology of preterm birth (PTB) (11). Animal mod-
els of intrauterine inflammation identify the fetal intestine as a 
potential site for the initiation of immune activation (12–14). The 
existence of organized intestinal lymphoid structures by the sec-
ond trimester (15) and the presence of antigens within swallowed 
amniotic fluid point to an instructive role for the intestinal muco-
sa in the development of fetal adaptive immunity. However, the 
identity of the effector T cells that contribute to the initiation of 
inflammation in the human fetal intestine is not known.
Protective fetal adaptive immunity can develop in response to 
specific pathogens and vaccines (16, 17), and memory T cells are 
present in the fetus and infant (18–22), indicating that adaptive 
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cells in the development of protective immunity and their contribu-
tion to perinatal immune dysregulation is not known.
Here, we performed a detailed analysis of human CD4+ T cell 
phenotype and function in fetal lymphoid and mucosal tissues. We 
show that Vα7.2–PLZF+TCR-αβ+CD4+ T cells (herein referred to as 
PLZF+CD4+ T cells) specifically accumulated in the fetal intestine 
and were absent from the adult. Fetal PLZF+CD4+ T cells repre-
sent a transcriptionally unique subset of CD4+ T cells that are 
distinct from either innate-like, semi-invariant Va7.2+ T cells or 
PLZF–CD4+ T cells. Consistent with a primarily T effector memo-
memory originates in utero. Innate-like T cells with rapid effector 
functions, such as γδ T cells, mucosa-associated invariant T (MAIT) 
cells, and innate-like NKT cells, are also present in fetal tissues (23–
25). Promyelocytic leukemia zinc finger (PLZF), a transcriptional 
regulator that directs the differentiation of innate-like T cells (26, 
27), is widely expressed in human immune cells and is commonly 
associated with expression of CD161, a C-type lectin receptor (28). 
The human fetal thymus uniquely produces a subset of CD4+ T cells, 
distinct from NKT cells and MAIT cells, that expresses the tran-
scription factor PLZF (29). However, the role of fetal PLZF+CD4+ T 
Figure 1. PLZF+Vα7.2–CD4+TCR-αβ+ T cells are highly abundant in the fetal intestine. (A) Representative flow plots of sequential gating strategy for the 
identification of intestinal memory T cells indicating the proportion of fetal intestinal effector memory (CD45RO+CD45RA–CCR7–) CD4+TCR-αβ+ T cells 
that express PLZF and CD161. (B) Frequencies of PLZF+ and PLZF– cells among effector memory CD4+TCR-αβ+ T cells of the fetal SI. (C) Representative 
imaging of PLZF expression among CD3+CD4+ T cells in tissue sections of the SI (n = 3). Arrowheads indicate triple-positive cells. Scale bar: 50 mm. Original 
magnification, ×400. (D) Representative flow plots of PLZF and CD161 expression among Vα7.2–CD4+TCR-αβ+ T cells in fetal tissues. (E) Frequencies of 
PLZF+Vα7.2–CD4+TCR-αβ+ T cells and (F) proportion of CD161+ cells among PLZF+Vα7.2–CD4+TCR-αβ+ T cells in fetal tissues. MLN, mesenteric lymph node; 
Spl., spleen; Liv., liver; Lu, lung. (G) Association between frequencies of intestinal PLZF+Vα7.2–CD4+TCR-αβ+ T cells and gestational age (GA), Spearman’s 
rank correlation. Numbers in flow cytometry plots correspond to the mean ± SD of gated populations. Circles represent individual donors. Box plot 
whiskers span minimum and maximum; lines represent median. **P < 0.01; ***P < 0.001; ****P < 0.0001, Wilcoxon’s matched-pairs signed rank test (B), 
Kruskal-Wallis paired ANOVA with Dunn’s multiple comparison test (E and F). 
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kine production in PLZF+CD4+ T cells, which, unlike their PLZF– 
counterparts, were resistant to glucocorticoid-induced apoptosis.
We propose a model in which functional maturation of 
PLZF+CD4+ T cells occurs in a spatially defined manner in the 
fetal small intestine (SI), where CD161 contributes to the regu-
lation of their effector function and allows for the accumulation 
of potentially proinflammatory cells within the tightly regulated, 
tolerogenic fetal environment. Further, the intestinal segregation 
of PLZF+CD4+ T cells positions them at a critical interface for the 
initiation of the fetal inflammatory response associated with many 
fetal and neonatal morbidities.
ry (TEM) phenotype, PLZF+CD4+ T cells rapidly produced TNF-α 
and IFN-γ in response to both T cell receptor (TCR) activation and 
cytokine stimulation. Engagement of CD161, coexpressed on the 
majority of intestinal PLZF+CD4+ T cells, inhibited TCR-mediat-
ed activation in a fetal-specific manner. PLZF+CD4+ T cells with 
enhanced capacity for Th1 cytokine production accumulated in 
the cord blood of infants with gastroschisis, an abdominal wall 
defect associated with systemic inflammation originating from 
intestinal injury (30), and were also increased in the cord blood of 
preterm infants. Finally, dexamethasone, routinely prescribed to 
pregnant women in impending preterm labor, inhibited Th1 cyto-
Figure 2. Fetal PLZF+CD4+ T cells exhibit a memory phenotype. (A) Representative flow plots of CD45RA vs. CD45RO (top) and CD45RA vs. CCR7 
(bottom) expression among indicated populations of Vα7.2–CD4+TCR-αβ+ cells in fetal SI. (B) Frequencies of memory (CD45RA–CD45RO+) and naive 
(CD45RA+, CD45RO–, CCR7+) cells among SI CD4+ T cells. (C) Frequencies of TEM within subsets of Vα7.2–CD4+TCR-αβ+ cells in fetal SI, LI, MLN, and 
spleen (SPL). (D) Representative flow plots of Ki67 expression among SI naive, central memory, and effector memory Vα7.2–CD4+TCR-αβ+ cells. (E) 
Frequencies of proliferating cells among paired samples of SI and MLN Vα7.2–CD4+TCR-αβ+ cells. (F–G) (F) Representative flow plots and (G) frequencies 
of endogenous Nur77 expression among SI and MLN T cells. Circles represent individual donors. Box plot whiskers span minimum and maximum; lines 
represent median. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001, Kruskall-Wallis paired ANOVA with Dunn’s multiple comparison test (B, C, E) 
and Mann-Whitney U test (G). Numbers in flow cytometry plots represent frequencies of gated populations ± SD.
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mucosal memory T cells (34, 35), most fetal intestinal PLZF+CD4+ 
T cells were CD69+, and a fraction of these (~20%) also expressed 
CD103, suggestive of a T resident memory (TRM) phenotype 
(Supplemental Figure 2, C and D). We examined the draining 
lymph nodes for endogenous expression of Nur77, induction of 
which is specific to antigen receptor signaling in human T cells 
(36). Ex vivo Nur77 expression was significantly more frequent 
among PLZF+CD4+ T cells of the MLN as compared with those 
of the intestine and was consistently low among PLZF–CD4+ T 
cells (Figure 2, F and G, and Supplemental Figure 2E). These data 
indicate that fetal PLZF+CD4+ T cells primarily comprise effector 
memory phenotype cells as well as a small but highly proliferative 
fraction of naive T cells. Endogenous Nur77 expression provides 
evidence of in situ TCR signaling in tissue-draining lymph nodes, 
which may contribute to the activation of fetal PLZF+CD4+ T cells.
Fetal PLZF+CD4+ T cells are a transcriptionally distinct popula-
tion of intestinal T cells. We characterized the global gene expres-
sion profile of PLZF+CD4+ T cells to examine their relationship 
to semiinvariant Vα7.2+CD161+ T cells and conventional memory 
PLZF–CD4+ T cells of the fetal SI (Supplemental Figure 3A and 
Supplemental Table 1). We isolated semiinvariant innate T cells 
by sorting TCR-αβ+Vα7.2+CD161+ cells (Supplemental Figure 3B), 
which exhibit phenotypic and functional characteristics of innate 
T cells (24). Of these, only a small fraction (4% ± 2%) were MR1 
tetramer–positive MAIT cells (Supplemental Figure 3C) (37). Dif-
ferential expression of IL-18R and PD1 allowed for the separation 
of PLZF+ from PLZF– memory CD4+ T cells (Supplemental Figure 
3, A and B). The expression of ZBTB16, IL18R, PDCD1, and KLRB1 
(the respective genes for PLZF, IL18R, PD1, and CD161) mirrored 
their protein expression and validated our sorting strategy (Sup-
plemental Figure 3, D and E). Intestinal PLZF+CD4+ T cells were 
significantly distinct from both Vα7.2+CD161+ T cells and PLZF– 
memory CD4+ T cells (permutational multivariate ANOVA [PER-
MANOVA], P < 0.001, r2 = 0.92), reflecting a divergent transcrip-
tional state by principal component analysis (PCA) (Figure 3A).
Comparison with Vα7.2+CD161+ T cells revealed 278 genes that 
were differentially enriched in PLZF+CD4+ T cells (>2-fold, FDR < 
0.05) (Figure 3B and Supplemental Table 2). In contrast to semiin-
variant Va7.2+CD161+ T cells, which preferentially expressed tran-
scripts for TCR-β variable 9 (TRBV9), TRBV7–9, and TRBV6–4, 
suggestive of an oligoclonal repertoire, PLZF+CD4+ T cells were 
enriched for multiple TCR-α variable (TRAV) genes and did not 
display preferential TRBV gene expression (Figure 3C). The diver-
sity of the T cell repertoire of PLZF+CD4+ T cells was supported 
by similar Vβ use among both PLZF+ and PLZF– memory CD4+ T 
cells and was comparable to that reported in fetal blood (38), with 
no single chain accounting for more than 10% of TCR-Vβ families 
(Figure 3D).
Consistent with a memory phenotype, similarities between SI 
PLZF+CD4+ T cells and conventional PLZF–CD4+ T cells revealed 
transcriptional overlap in the expression of genes associated with 
T cell activation and memory (21) (Supplemental Figure 4A). We 
identified 499 genes that differentiated these 2 memory popula-
tions (>2-fold, FDR < 0.05) (Figure 3B and Supplemental Table 3) 
and utilized the Human Primary Cell Atlas to identify genes that 
cluster together by cell type using correlation analysis (39). This 
approach identified 6 gene clusters, of which clusters 1, 2, and 4 
Results
PLZF+CD4+ T cells are highly abundant in the fetal intestine. The 
presence of adaptive memory in the second trimester human fetal 
intestine (19, 21, 22) led us to examine the composition of these 
memory T cells. As many human innate cells express PLZF (28), 
we restricted our analysis to TCR-αβ+Vα7.2–CD4+ T cells (herein 
referred to as CD4+ T cells), which excluded MAIT cells, γδ T cells, 
NK cells, and innate lymphoid cells (Supplemental Figure 1; sup-
plemental material available online with this article; https://doi.
org/10.1172/JCI125957DS1). Intestinal memory CD4+ T cells were 
predominantly of an effector memory phenotype (CD45RO+C-
D45RA–CCR7–) (TEM); the majority of these expressed PLZF 
(Figure 1, A and B). Immunofluorescent microscopy confirmed 
abundant PLZF expression among lamina propria (LP) CD4+ T 
cells (Figure 1C). In stark contrast to the adult SI or large intes-
tine (LI), the accumulation of PLZF+CD4+ T cells was specific to 
fetal tissues (Figure 1, D and E). PLZF+CD4+ T cells accounted for 
approximately 30% and approximately 35% of CD4+ T cells of the 
fetal SI and LI, respectively, and averaged less than 10% of CD4+ 
T cells across other fetal tissues. CD161, the human homolog of 
the murine NK cell receptor NKR-P1, is expressed by many human 
T cell subsets, including TCR-γδ and TCR-αβ T cells, MAIT cells, 
and NKT cells, and is associated with adult memory T cells (26, 
27, 31, 32). Tissue-specific patterns of CD161 coexpression indi-
cated significantly higher proportions of CD161+ cells among 
PLZF+CD4+ T cells in the fetal SI compared with those in lymphoid 
tissue and liver (Figure 1, D and F). Although thymic production of 
PLZF+CD4+ T cells declines in the third trimester (29), the intesti-
nal accumulation of PLZF+CD4+ T cells was positively associated 
with advancing gestation and could in part explain the observed 
variability among samples (Figure 1G).The age-associated and 
fetal-specific enrichment of PLZF+CD4+ T cells suggest a specific 
adaptation to the in utero environment.
The majority of fetal PLZF+CD4+ T cells exhibit a memory phe-
notype. PLZF is the master regulator of the effector phenotype in 
murine innate-like populations (26, 27), which led us to examine 
whether human fetal SI PLZF+CD4+ T cells uniformly expressed 
a TEM phenotype. Compared with SI CD4+ T cells which did not 
express PLZF, PLZF+CD4+ T cells possessed significantly higher 
proportions of memory cells and fewer naive cells (Figure 2, A 
and B). Although the majority of SI PLZF+CD4+ T cells expressed 
CD45RO and lacked expression of both CD45RA and CCR7 (85% 
of PLZF+CD161+ and 60% of PLZF+CD161–), a naive phenotype 
was consistently evident among PLZF+CD4+ T cells. A naive-like 
CD1d-restricted T cell population with reduced levels of PLZF 
expression is present in humans, and murine transgenic studies 
demonstrate that a threshold level of PLZF expression is required 
for effector conversion (33). Similarly, naive phenotype fetal 
PLZF+CD4+ T cells expressed lower levels of PLZF compared with 
those with a memory phenotype (Supplemental Figure 2, A and 
B). The predominantly TEM phenotype of PLZF+CD161+CD4+ T 
cells was conserved across lymphoid tissues (Figure 2C). Ex vivo 
Ki-67 staining of intestinal and mesenteric lymph node (MLN) T 
cells demonstrated significantly more proliferation among naive 
PLZF+CD4+ T cells as compared with their PLZF– counterparts, 
whereas proliferation among memory cells was comparable 
between the 2 populations (Figure 2, D and E). Similar to adult 
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Figure 3. PLZF+CD4+ T cells are a transcriptionally distinct population 
of intestinal T cells. (A) PCA of the top 1000 variable genes identified by 
RNA-Seq of fetal intestinal PLZF+CD4+ T cells (n = 5), PLZF–CD4+ T cells (n 
= 4), and Vα7.2+CD161+ T cells (n = 5). Ellipses denote the 95% confidence 
intervals of population means (PERMANOVA R2 0.92, P < 0.001). Box 
plots indicate scores for PC1 (bottom) and PC2 (right). (B) Numbers of 
genes with more than 2-fold (FDR < 0.05) increase (red) or decrease 
(white) in expression levels between populations. (C) DE genes (>2 fold, 
FDR < 0.05) in PLZF+CD4+ T cells compared with Vα7.2+CD161+ T cells. DE 
genes (dark grey), TCR genes, enriched (orange) or diminished (purple), in 
PLZF+CD4+ T cells are labeled. (D) Frequencies (mean ± SEM) of expres-
sion of 21 TCR-Vβ chains by flow cytometry in fetal intestinal PLZF+CD4+ 
T cells (red) compared with PLZF–CD4+ T cells (white). Circles indicate 
individual donors. (E) Heatmap shows color-coded relative enrichment 
of cluster 1 DE genes in PLZF+CD4+ T cells relative to PLZF–CD4+ T cells 
among indicated cell types identified by correlation analysis using the 
Human Primary Cell Atlas. Box indicates lymphoid-enriched genes asso-
ciated with immune activation. (F) Multi-way comparison of DE genes 
(>2 fold, FDR < 0.05) in PLZF+CD4+ T cells compared with Vα7.2+CD161+ 
T cells (y axis) and compared with PLZF–CD4+ T cells (x axis) identifies 
a core signature of genes uniquely enriched (red) and diminished (blue) 
within intestinal PLZF+CD4+ T cells. Selected genes involved in immune 
response, immune regulation, and leukocyte migration are labeled.
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were enriched for transcripts involved in the immune response 
(Supplemental Figure 4, B and C). Cluster 1 contained significant 
overlap with lymphoid-associated genes, and clusters 2 and 4 
comprised predominantly myeloid-associated genes (Supplemen-
tal Figure 4, D and E). Immune activation genes in cluster 1 over-
lapped with those enriched in TEM cells, NK cells, and γδ T cells 
and were suggestive of Th1-effector (IFN-G, CXCR3, XCL1) and 
cytotoxic functions (GZMB, GZMK, FASLG; Figure 3E). Myeloid 
genes in clusters 2 and 4 were associated with the immune 
response and regulation of the immune response (Supplemental 
Figure 4, B–D). The atypical composition of myeloid- and lym-
phoid-associated genes in the transcriptome of fetal intestinal 
PLZF+CD4+ T cells suggested shared attributes with both innate 
and adaptive immune cells.
We identified a core signature of 111 genes that were enriched 
and 137 genes that were depleted in PLZF+CD4+ T cells com-
pared with both PLZF–CD4+ memory T cells and Va7.2+CD161+ T 
cells (>2 fold change; FDR < 0.05) (Figure 3F and Supplemental 
Table 4). The core signature of PLZF+CD4+ T cells contained tran-
scripts involved in T cell activation (IL2, CD40LG, IL18R1, IL2RB, 
Figure 4. PLZF+CD4+ T cells possess Th-1 effector 
potential. (A) Representative flow plots of intra-
cellular TNF-α and IFN-γ staining of indicated popu-
lations of SI- and MLN-derived Vα7.2–TCR-αβ+CD4+ T 
cells following PMA/ionomycin stimulation (n = 18). 
(B, C) Frequencies of (B) IFN-γ+ and (C) TNF-α+ cells 
within indicated populations of Vα7.2+TCR-αβ+CD4+ 
T cells after PMA/ionomycin stimulation with-
in fetal SI (n = 18), MLN (n = 11), spleen (n = 5), 
and thymus (THY) (n = 6). (D and E) Association 
between (D) IFN-γ and (E) TNF-α production by SI 
PLZF+CD4+ T cells in response to PMA/ionomycin 
and GA, Spearman’s rank correlation. (F–H) (F) 
Representative flow plots of and frequencies of 
(G) IL-4 and (H) IL-17 production among indicated 
populations of SI- and MLN-derived Vα7.2– Va24–
TCR-αβ+CD4+ T cells following PMA/ionomycin 
stimulation. Numbers in flow cytometry plots cor-
respond to the mean ± SD of gated populations. Cir-
cles represent individual donors. Box plot whiskers 
span minimum and maximum, and lines represent 
median. Kruskal-Wallis paired ANOVA with Dunn’s 
multiple comparison test (B, C, G, H). *P < 0.05; **P 
< 0.01; ***P < 0.001; ****P < 0.0001.
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Figure 5. PLZF+CD4+ T cells produce cytokines in response to both TCR-dependent and TCR-independent activation. All T cell populations gated on 
live Vα7.2–CD4+TCR-αβ+ cells. (A and B) Frequencies of (A) IFN-γ+ and (B) TNF-α+ cells within indicated populations of CD4+ T cells of the SI and LI after 
stimulation with anti-CD3+ anti-CD28. (C–F) (C) Representative flow cytometry plots and frequencies of (D) IFN-γ+ and (E) TNF-α+ cells within indicated 
populations of SI CD4+ T cells after stimulation with anti-CD3+ anti-CD28 for 24 hours. (F) Frequencies of IFN-γ+ cells within indicated populations of intes-
tinal TEM (left) and TCM (right) CD4+ T cells after stimulation with anti-CD3+ anti-CD28 for 24 hours. (G) Representative flow plots of intracellular Nur77 
staining in intestinal CD4+ TEM cells after 4 hours of anti-CD3+ anti-CD28 stimulation. Mean frequency ± SD of gated populations (n = 7). (H) Frequencies 
of induced Nur77 expression within indicated populations of intestinal CD4+ TEM cells after 4 hours of anti-CD3+ anti-CD28 stimulation. Lines join paired 
samples. (I and J) Frequencies of (I) IFN-γ+ cells and (J) TNF-α+ among intestinal PLZF+ and PLZF–CD4+ T cells in response to cytokine stimulation with IL-12 
plus IL-18 for 24 hours. (K) Frequencies of IFN-γ+ cells within PLZF+CD4+ T cells of the SI and thymus in response to cytokine stimulation with IL-12 plus 
IL-18 for 24 hours. Numbers in flow cytometry plots correspond to the mean ± SD of gated populations. Box plot whiskers span minimum and maximum; 
lines represent median. Circles represent individual donors. Kruskal-Wallis paired ANOVA with Dunn’s multiple comparison test (A, B, D, E, I), Mann-Whit-
ney U test (K), and Wilcoxon’s matched-pairs signed rank test (F, H, J). *P < 0.05, **P < 0.01t.
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compared with those of the MLN, spleen, or thymus (Figure 4B). 
TNF-α was abundantly produced by all fetal CD4+ T cells, yet pro-
duction of TNF-α was significantly more frequent among PLZF+ 
as compared with PLZF–CD4+ T cells (Figure 4C). The proportion 
of IFN-γ–producing intestinal PLZF+CD4+ T cells increased with 
advancing gestation, while the ability to produce TNF-α was not 
significantly associated with gestational age (GA) (Figure 4, D and 
E). Among PLZF–CD4+ T cells, neither the ability to produce IFN-γ 
nor TNF-α correlated with advancing gestation (Supplemental 
Figure 5, C and D). PLZF has been associated with production of 
Th2-type cytokines (26, 27), yet production of IL-4 did not differ 
significantly between PLZF+ and PLZF–CD4+ T cells (Figure 4, F 
and G) and fetal IL-10–producing CD4+ T cells were nearly unde-
tectable (Supplemental Figure 5E). PLZF is required for the differ-
entiation of human Th17 cells (43), and although low in frequency, 
IL-17–producing cells were significantly more abundant among 
PLZF+CD4+ T cells in both the MLN and the intestine (Figure 4, 
F and H). Consistent with the presence of IL-2 in their core signa-
ture (Figure 3F), a greater proportion of SI PLZF+CD4+ T cells pro-
duced IL-2 than PLZF- CD4+ T cells (Supplemental Figure 5, F and 
MAP3K8, PIK3R1) as well as T cell regulation (DUSP4, DUSP5, 
DUSP6, LRIG1, and DTX1). Among the genes specifically depleted 
in PLZF+CD4+ T cells were those required for lymph node homing 
and tissue egress (SELL, CCR7, S1PR1, KLF2) (40, 41), supporting 
the characterization of some of these cells as human TRM cells. In 
sum, Vα7.2– PLZF+CD4+ TCR-αβ+ cells represent a transcriptional-
ly distinct subset of intestinal T cells with a diverse TCR repertoire 
and share gene expression profiles with innate immune cells, sug-
gestive of a rapid effector function.
Fetal PLZF+CD4+ T cells possess inflammatory potential. We 
next examined the effector potential of SI PLZF+CD4+ T cells in 
response to short-term stimulation with PMA and ionomycin. 
SI PLZF+CD4+ T cells robustly produced Th1 cytokines: on aver-
age 55% produced TNF-α and 28% produced IFN-γ (Figure 4A). 
Although CD161 is associated with maturation of effector function 
in human T cells (42), production of TNF-α and IFN-γ was simi-
lar among CD161+ and CD161– PLZF+CD4+ T cells (Supplemental 
Figure 5, A and B). A significantly larger proportion of PLZF+CD4+ 
T cells produced IFN-γ compared with PLZF–CD4+ T cells, and a 
larger fraction of intestinal PLZF+CD4+ T cells produced IFN-γ 
Figure 6. CD161 inhibits cytokine production in SI PLZF+CD4+ T cells. (A) Representative histograms of LLT1 expression among intestinal lineage– HLA-
DR+CD14+ APCs (n = 10). (B) Representative flow plots of intracellular cytokine staining in PLZF+CD4+ T cells after stimulation with anti-CD3+ anti-CD28 in 
the presence of 2 different clones of crosslinked anti-CD161 antibodies or isotype controls (10 mg/ml). (C and D) Relative proportion of (C) IFN-γ and (D) 
TNF-α production by SI PLZF+CD4+ T cells normalized to isotype response after stimulation with anti-CD3+ anti-CD28 in the presence of crosslinked anti-
CD161 antibodies. (E) Relative proportions of IFN-γ production by SI PLZF+CD4+ T cells normalized to isotype response after stimulation with IL-12+ IL-18 in 
the presence of crosslinked anti-CD161 antibody. (F) Relative proportion of IFN-γ (left panel) and TNF-α (right panel) production by adult CD161+CD4+ T cells 
normalized to isotype response after stimulation with anti-CD3+ anti-CD28 in the presence of crosslinked anti-CD161 antibodies. Lines represent mean. 
Each color represents an individual donor. Numbers in flow cytometry plots represent mean frequency ± SD of the gated populations. LME modeling in 
comparison with lowest dose (C and D). *P < 0.05; **P < 0.01.
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phenotype. SI PLZF+CD4+ T cells were more responsive to in vitro 
TCR activation, resulting in a higher proportion of cells producing 
both IFN-γ and TNF-α compared with PLZF–CD4+ T cells (Figure 
5, A and B). In contrast, the proportion of PLZF+CD4+ T cells of 
the LI capable of IFN-γ production was minimal, suggesting com-
partmentalization of the effector potential along the intestine. The 
IFN-γ response of both PLZF+ and PLZF–CD4+ T cells segregated 
with their maturation state with significantly higher proportions of 
G), and production of IL-8 (CXCL8) was equivalent between these 
populations (Supplemental Figure 5, H and I). In sum, PLZF+CD4+ 
T cells are a polyfunctional effector population and a potentially 
abundant source of Th1 cytokines among fetal CD4+ T cells.
Fetal PLZF+CD4+ T cells produce cytokines in response to both 
TCR-dependent and TCR-independent activation. The striking 
potential of fetal SI PLZF+CD4+ T cells to produce Th1 cytokines 
led us to investigate the stimulatory signals required to elicit this 
Figure 7. IFN-γ–producing fetal PLZF+CD4+ T cells are enriched in the cord blood of infants with systemic inflammation. (A) Representative flow plots 
of PLZF and CD161 expression and (B) frequencies of PLZF+ cells in Vα7.2– TCR-αβ+CD4+ T cells in the cord blood (CB) of infants with gastroschisis (GS) and 
healthy controls. (C) Frequencies of naive, TCM, TEM, and TEMRA cells among cord blood PLZF+CD4+ T cells in infants with gastroschisis (n = 8) compared 
with healthy controls (n = 23). (D and E) Frequencies of (D) IFN-γ+ and (E) TNF-α+ cells within PLZF+ (left) and PLZF– (right) populations of cord blood 
Vα7.2–TCR-αβ+CD4+ T cells in healthy controls compared with infants with gastroschisis after PMA/ionomycin stimulation. (F) Representative flow plots 
of PLZF and CD161 expression and (G) frequencies of cord blood PLZF+CD4+ T cells in healthy controls and PTB samples. (H) Representative flow plots of 
TNF-α and IFN-γ production among indicated populations of cord blood Vα7.2–TCR-αβ+CD4+ T cells in PTB samples after PMA/ionomycin stimulation. (I 
and J) Frequencies of (I) IFN-γ+ and (J) TNF-α+ cells within PLZF+ (left) and PLZF– (right) populations of cord blood Vα7.2–TCR-αβ+CD4+ T cells in healthy 
controls compared with PTB samples after PMA/ionomycin stimulation. Circles represent individual donors. Bar graphs represent mean with SD. Box plot 
whiskers span minimum and maximum; lines represent median. Mann-Whitney U test (B–E, G, I, J). **P < 0.01; ***P < 0.001; ****P < 0.0001.
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produce IFN-γ in response to either TCR- or cytokine-mediated 
activation and indicate an association between effector memory 
phenotype and function.
CD161 inhibits cytokine production in SI PLZF+CD4+ T cells. The 
dual activation potential of SI PLZF+ T cells led us to hypothesize 
that their effector function would be tightly regulated. CD161 is 
expressed by the majority of SI PLZF+CD4+ T cells (Figure 1, D 
and F) and has been ascribed conflicting roles in either the acti-
vation or inhibition of human immune cells (45–47). LLT1, the 
natural ligand for CD161, is broadly distributed in human tissues, 
with the highest levels of expression in immune-privileged sites 
(48, 49). LLT1 was expressed on the majority of intestinal CD14+ 
antigen-presenting cells (APCs), but not CD11c+CD14– DCs (Fig-
ure 6A and Supplemental Figure 7, A and B). Intestinal CD14+ 
APCs were CD68+, CD163+, CD209+, and CD103– and expressed 
intermediate levels of HLA-DR, consistent with a tissue-resident 
macrophage phenotype (50) (Supplemental Figure 7C). Segre-
gation of LLT1 expression to intestinal macrophages, which in 
adult intestine exhibit antiinflammatory properties (51), led us to 
explore the role of CD161 in the regulation of fetal SI PLZF+CD4+ 
T cells. Crosslinking of CD161 on SI PLZF+CD4+ T cells during 
TCR activation resulted in a dose-dependent inhibition of Th1 
cytokines, although this effect was only significant for IFN-γ 
(Figure 6, B–D). Two different clones of monoclonal antibodies 
to CD161 were equally effective at a high dose (10 μg/mL), and 
clone HP3G10 inhibited cytokine production at a lower dose (10–1 
μg/mL). Engagement of CD161 had no effect on SI PLZF+CD4+ T 
IFN-γ–producing cells among TEM phenotype cells and minimal 
IFN-γ production among either intestinal naive cells or mature 
thymocytes (Figure 5, C and D, and Supplemental Figure 6A). In 
contrast, TNF-α production did not differ significantly between 
naive and memory phenotypes for either PLZF+ or PLZF–CD4+ T 
cells (Figure 5E and Supplemental Figure 6B). SI PLZF+CD4+ T 
cells with either a TEM or T central memory (TCM) phenotype 
produced significantly more IFN-γ than their PLZF– counterparts, 
and a similar trend was observed for TNF-α (Figure 5F and Supple-
mental Figure 6C), suggesting that the enhanced cytokine produc-
tion of SI PLZF+CD4+ T cells could not be attributed to the preva-
lence of a memory phenotype. In vitro activation of fetal T cells 
induced significantly higher proportions of Nur77-expressing cells 
in SI PLZF+ TEM cells compared with PLZF– TEM cells (Figure 5, G 
and H), suggesting a lower TCR signaling threshold.
Transcriptional overlap with innate-like T cells and myeloid 
cells (Figure 3E and Supplemental Figure 4, D and E) prompted us 
to assess the response of SI PLZF+CD4+ T cells to TCR-indepen-
dent activation. SI PLZF+CD4+ T cells produced IFN-γ, but not 
TNF-α, in response to the combination of IL-12 and IL-18 (Figure 
5, I and J, and Supplemental Figure 6D). Unlike classical innate-
like T cells, which acquire effector function during thymic devel-
opment (44), thymic PLZF+CD4+ T cells did not produce detect-
able IFN-γ in response to these cytokines (Figure 5K). The ability 
to respond to cytokines alone was significantly greater among 
PLZF+CD4+ TEM cells than PLZF–CD4+ TEM cells (Supplemental 
Figure 6E). Our data reveal that SI PLZF+ TEM cells are poised to 
Figure 8. SI PLZF+CD4+ T cells are 
resistant to glucocorticoid-induced 
apoptosis. (A and B) (A) Representa-
tive flow plots of annexin V and via-
bility dye and (B) frequencies of viable 
cells among SI PLZF+ and PLZF–CD4+ 
T cells cultured in the presence of indi-
cated doses of dexamethasone (Dex) 
or ethanol vehicle control (VC) for 36 
hours. (C) Representative flow plots of 
intracellular IFN-γ and TNF-α staining 
among SI PLZF+ and PLZF–CD4+ T cells 
after stimulation with anti-CD3/anti-
CD28/anti-CD2 beads in the presence 
of dexamethasone or vehicle control. 
(D and E) Frequencies of IFN-γ– (left) 
and TNF-α –producing (right) (D) SI 
PLZF+CD4+ T cells and (E) SI PLZF–
CD4+ T cells after stimulation with 
anti-CD3/anti-CD28/anti-CD2 beads 
in the presence of dexamethasone 
or vehicle control. Circles represent 
individual donors. Numbers in flow 
cytometry plots represent mean fre-
quency ± SD of the gated populations. 
Wilcoxon’s matched-pairs signed rank 
test (D and E). *P < 0.05.
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(Figure 7, H–J), and the proportion of PLZF+CD4+ T cells capable 
of Th1 cytokine production was consistently higher than that of 
their PLZF– counterparts (Supplemental Figure 9E). In sum, our 
data indicate that PLZF+CD4+ T cells with increased Th1 effector 
potential accumulate in the circulation of infants with gastroschi-
sis as well as infants with PTB, suggesting that they may contribute 
to prenatal immune activation.
Glucocorticoids exert antiinflammatory effects on fetal 
PLZF+CD4+ T cells. Maternal antenatal corticosteroid therapy with 
betamethasone or dexamethasone is one of the most effective 
interventions to improve the outcomes of premature infants. Both 
drugs cross the placenta and have equivalent immunosuppressive 
function, yet their effect on human fetal T cells is not known. In 
contrast to PLZF–CD4+ T cells, PLZF+CD4+ T cells were relatively 
resistant to glucocorticoid-induced apoptosis (Figure 8, A and B). 
This discordant response was also evident among CD45RA- CD4+ 
T cells and thus could not be attributed to a greater proportion of 
naive cells among PLZF–CD4+ T cells (Supplemental Figure 10). 
PLZF+CD4+ T cells are differentially enriched for the antiapoptot-
ic BCL-2 homolog A1 (BCL2A1) (Supplemental Figure 4A), which 
may contribute to their survival (55). However, dexamethasone 
significantly inhibited the ability of both SI PLZF+ and PLZF–CD4+ 
T cells to produce Th1 cytokines (Figure 8, C and D). Thus, despite 
resistance to apoptosis, PLZF+CD4+ T cells are susceptible to the 
antiinflammatory effects of glucocorticoids routinely used in 
antenatal therapy.
Discussion
Perinatal inflammatory pathologies are a primary cause of mor-
bidity and mortality in the fetus and newborn and may affect the 
developing brain (neurocognitive disorders, cerebral palsy), lung 
(bronchopulmonary dysplasia), and intestine (necrotizing entero-
colitis) (56). Given the contribution of T cells to the fetal inflam-
matory response, an understanding of fetal effector T cell identi-
ty, function, and regulation is essential for the design of effective 
strategies to treat or prevent these illnesses. Mouse models have 
provided critical mechanistic insight of neonatal T cell responses in 
vivo (57), yet extrapolating findings between species is hampered 
by substantial differences in the timing of immune development 
(1). This study examines the characteristics of human fetal CD4+ 
T cells in lymphoid and mucosal tissues and reveals an abundant 
population of fetal PLZF+Vα7.2–TCR-αβ+CD4+ cells with Th1 effec-
tor potential that is not present in the adult intestine. The broad 
distribution of PLZF+CD4+ T cells in lymphoid organs and the pre-
dominant accumulation of effector function in the intestine sug-
gest a role for these cells in fetal immune surveillance and defense.
In utero development occurs under unique conditions that 
may contribute to the fetal-specific intestinal accumulation of 
PLZF+CD4+ T cells. Human fetal lymph nodes are enriched for 
TGF-β and TNF-α (4), cytokines associated with homeostatic pro-
liferation and murine TRM development (58), suggesting a role 
for cytokine signaling in the expansion and intestinal homing of 
PLZF+CD4+ T cells. The robust response of fetal T cells to mater-
nal antigens (59) is actively suppressed by fetal Tregs (4, 60), and 
expression of endogenous Nur77 in MLN-derived PLZF+CD4+ T 
cells supports the hypothesis that antigen recognition may also 
inform the development of these cells. Reports of microbial pres-
cell IFN-γ production in response to cytokine stimulation alone 
(Figure 6E and Supplemental Figure 7D), which prompted us to 
examine the effect of CD161 engagement on TCR signaling. How-
ever, ligation of CD161 did not appreciably dampen induction of 
Nur77 in response to TCR activation (Supplemental Figure 7E). 
Consistent with previous reports (52), engagement of CD161 on 
adult CD4+ T cells did not significantly affect cytokine production 
(Figure 6F and Supplemental Figure 7F). Collectively, our results 
indicate that ligation of CD161 results in fetal-specific inhibition 
of cytokine production in response to TCR activation.
IFN-γ–producing fetal PLZF+CD4+ T cells are enriched in the 
umbilical cord blood of infants with systemic inflammation. We next 
asked whether we could detect effector PLZF+CD4+ T cells in the 
circulation of infants with gastroschisis, a congenital abdominal 
wall defect associated with systemic fetal inflammation thought 
to originate from the intestine (30) (Supplemental Table 5). While 
present in low numbers in healthy term infants, PLZF+CD4+ T 
cells were enriched in the cord blood of infants with gastroschisis 
(Figure 7, A and B). The composition of circulating PLZF+CD4+ T 
cells reflected that of the fetal intestine, with significantly more 
effector and memory cells in contrast to the primarily naive phe-
notype of PLZF–CD4+ T cells (Supplemental Figure 8, A–C). Con-
sistent with an increase in the relative frequency of terminally dif-
ferentiated effector memory (TEMRA) cells (Figure 7C), a subset 
of TEM cells that reexpress CD45RA after antigenic stimulation, 
PLZF+CD4+ T cells from gastroschisis samples exhibited high-
er proportions of IFN-γ–producing cells compared with healthy 
controls (Figure 7D and Supplemental Figure 8D). An increase in 
the proportion of TNF-α–producing cells among both PLZF+ and 
PLZF–CD4+ T cells was also observed (Figure 7E and Supplemen-
tal Figure 8D). The Th1 effector potential of cord blood PLZF+ T 
cells was consistently greater than that of their PLZF– counter-
parts in both healthy controls and infants with gastroschisis (Sup-
plemental Figure 8, E and F).
The accumulation of circulating effector PLZF+CD4+ T cells 
during a systemic inflammatory response originating from the 
intestine led us to examine their involvement in the Th1-mediat-
ed immune activation associated with PTB (11). Analysis of pub-
lished gene expression data sets (53, 54) revealed that expression 
of ZBTB16, the gene encoding PLZF, was significantly increased 
in the cord blood of PTB samples compared with term controls in 
2 independent cohorts (Supplemental Figure 9A). We examined 
cord blood samples from PTB (<37 weeks) infants (Supplemen-
tal Table 6), which reaffirmed the previously reported increase 
in TCM cells and the concomitant decrease in naive cells among 
CD4+ T cells in PTB as compared with term (>37 weeks) controls 
(Supplemental Figure 9, B and C, and refs. 8, 11). In agreement 
with the gene expression analysis, the frequency of circulating 
PLZF+CD4+ T cells was significantly higher in PTB compared with 
term infants (Figure 7, F and G). The accumulation of PLZF+CD4+ 
T cells in the cord blood of PTB infants is less likely to be attributed 
to increased thymic production of these cells earlier in gestation, 
as the proportion of naive PLZF+CD4+ T cells was significantly 
lower than in term cord blood, with a concomitant increase in TEM 
cells (Supplemental Figure 9, B and D). Circulating PLZF+CD4+ T 
cells in PTB samples displayed a significantly greater capacity for 
IFN-γ and TNF-α production compared with those of term infants 
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tive immunity. Expression of PLZF is required for thymic dif-
ferentiation of NKT cells and is sufficient to confer a memory 
phenotype and effector function (26, 27). Similarly, acquisition 
of PLZF expression in MAIT cells coincides with the initiation 
of functional maturation in the thymus (71). Although PLZF is a 
master regulator of murine innate-like T cells, its contribution to 
lineage differentiation in humans appears to be more complex. 
Comparable to adult naive-like CD1d-restricted T cells (33), 
fetal naive PLZF+CD4+ T cells express reduced levels of PLZF 
compared with their memory phenotype counterparts. A cor-
relation between gradients of PLZF expression and acquisition 
of effector maturation is also evident during human Th17 devel-
opment (43), although unequivocal proof of this would necessi-
tate lineage-tracing studies that are not feasible in humans. It 
is possible that the differentiation program of fetal PLZF+CD4+ 
T cells is imprinted during thymic development; however, func-
tional maturation is not apparent in the thymus. Neither thy-
mus-derived nor naive phenotype PLZF+CD4+ T cells produce 
significant levels of IFN-γ, which, coupled with the increasing 
effector potential of SI PLZF+CD4+ T cells with advancing ges-
tation, suggests that additional maturation steps are required 
after thymic differentiation. A naive T cell phenotype supports 
lymph node–homing potential, a key step in the initiation of 
adaptive-like responses, which, together with evidence of anti-
gen-receptor activation in MLN-derived PLZF+CD4+ T cells, 
could suggest an adaptive-like process in the acquisition of 
functional maturation. Previous studies implicate MHC class 
II–dependent selection of PLZF+ T cells during thymic devel-
opment (29). Determining whether antigen recognition by fetal 
PLZF+CD4+ T cells in the periphery is restricted to MHC class 
II and understanding the specific nature of these antigens will 
help clarify the development of these cells in future studies. 
In contrast to the oligoclonal repertoire of innate-like T cells, 
PLZF+CD4+ T cells exhibited variable TCR-α and TCR-β chains, 
indicative of a polyclonal T cell population. Unlike MAIT cells 
and γδ T cells, which are hyporesponsive to TCR stimulation (72, 
73), fetal SI PLZF+ T cells demonstrated enhanced cytokine pro-
duction and a lower TCR signaling threshold than conventional 
PLZF– TEM cells. Thus, although fetal PLZF+CD4+ T cells pos-
sess important innate cell attributes, substantial transcription-
al, phenotypic, and functional differences set this subset apart 
from other innate-like T cells.
The inflammatory potential of fetal PLZF+CD4+ T cells may 
have broad implications for the health of the fetus during preg-
nancy and for newborns, particularly those that are born prema-
turely. The increased frequency of effector IFN-γ+PLZF+CD4+ 
T cells in the cord blood of infants with gastroschisis as well as 
infants born preterm supports a role for these cells in the fetal 
inflammatory response. The insult in gastroschisis is thought to 
originate from intestinal serosal exposure to amniotic fluid, and it 
is equally plausible that luminal insults result in the activation of 
mucosal immune cells. The association of bacteria in intraamniot-
ic infection and PTB is well established (74), suggesting that fetal 
SI PLZF+CD4+ T cells are ideally situated to encounter antigen or 
inflammatory modulators in swallowed amniotic fluid. Yet wheth-
er immune activation in the intestine contributes to the effector 
T cell pool in the circulation is unclear. In mice, the vast majori-
ence in human meconium and amniotic fluid (61–63) point to the 
growing importance of understanding the development of protec-
tive fetal immunity and the effects of bacterial priming that may 
occur in utero. Intestinal luminal antigens may also direct surface 
acquisition of LLT1 on fetal macrophages, as LLT1 expression is 
robustly elicited in human APCs in response to TLR and B cell 
receptor activation (49, 52, 64). Loss of placental hormones and 
the sudden increase in oxygen availability at birth, the introduc-
tion of an oral diet, and other environmental exposures likely exert 
different pressures on mucosal immune composition and may 
explain the absence of PLZF+CD4+ T cells from the adult intes-
tine. The emergence of the neonatal intestinal microbiome may 
allow for the expansion of new T cell populations that outcompete 
fetal SI PLZF+CD4+ T cells. Cell-intrinsic properties related to the 
developmental origin of fetal T cells (65, 66) may additionally 
contribute to the fetal-specific accumulation of SI PLZF+CD4+ T 
cells and the inhibitory effect of CD161 engagement. CD161 liga-
tion inhibits human NK cells (45, 64, 67), but exerts costimulato-
ry effects on NKT cells (46) and MAIT cells (47). Perhaps due to 
conditions unique to the in utero environment, our results demon-
strate a fetal-specific inhibitory effect that is the opposite of the 
primarily costimulatory role for CD161 on adult human innate T 
cells. CD161 signaling may influence activation downstream of 
TCR signaling, yet we did not observe an effect on expression of 
Nur77. Induction of Nur77 in human CD4+ T cells is dependent on 
PI3K and MEK, as well as Akt and mTOR complex 1 (mTORC1) 
and mTORC2, and less sensitive to mTORC1 alone and JAK/Stat 
signaling (36). CD161 engagement results in increased production 
of ceramide through induction of acid sphingomyelinase (ASM) 
activity and mediates downstream signaling cascades, includ-
ing STAT3 and mTOR (68, 69). Thus, the mechanism of CD161 
inhibition may involve JAK/Stat and mTORC1 signaling pathways 
independent of Nur77 induction and will be explored in future 
studies. The differential enrichment of numerous negative T cell 
regulators in the gene signature of SI PLZF+CD4+ T cells suggests 
the existence of additional cell-intrinsic mechanisms of regulation 
to promote immune homeostasis in utero.
Fetal SI PLZF+CD4+ T cells share functional and transcrip-
tional attributes with both conventional and innate-like T cells. 
The development of TRM cells is closely coupled to anatomic 
location (41, 70), suggesting that the intestinal microenviron-
ment may be responsible for the enhanced cytokine production 
of SI PLZF+CD4+ T cells as well as the preferential accumulation 
of CD161+ cells. The appearance of Th1 effector cells in the SI 
precedes that in the LI and supports the regional compartmen-
talization of the effector response. However, to what extent SI 
PLZF+CD4+ T cells recirculate to other organs and whether they 
represent a different population than those in lymphoid tissues 
is not known. A Th1 effector phenotype is also evident in human 
fetal γδ T cells, Vα7.2+CD161+ T cells, and NKT cells (23–25), yet 
unlike Vα7.2+CD161+ T cells and NKT cells, which make up on 
average approximately 1% of T cells in the fetal intestine (24, 
25), fetal PLZF+CD4+ T cells represent an unusually abundant 
proportion (~30%) of intestinal T cells. The transcriptional over-
lap with myeloid cells, in conjunction with the ability to respond 
to cytokines independently of TCR activation, suggests that 
these cells may serve as a link between fetal innate and adap-
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Kit (STEMCELL Technologies). Isolated cells were incubated in 2% 
FCS in PBS with 1 mM EDTA (staining buffer) with human Fc block 
(STEMCELL Technologies) and stained with fluorochrome-conju-
gated antibodies against surface markers. Intracellular protein detec-
tion was performed on fixed, permeabilized cells using the Foxp3/
Transcription Factor Staining Buffer Set (Tonbo Biosciences). Mouse 
anti-human mAbs used in this study included the following: TCR-αβ 
PerCP-e710 (clone IP26, eBioscience, catalog 46-9986-42), Vα7.2 bio-
tin and BV605 (clone 3C10, BioLegend, catalog 351724 and 351720), 
CD4 APC H7 (clone L200, BD Biosciences — Pharmingen, catalog 
560837), CD8α FITC (clone SK1, BD Biosciences, catalog 347313), 
CD8α PE (clone HIT8a, BD Biosciences, catalog 555635), CD45RA PE 
(clone HI100, BD Biosciences — Pharmingen, catalog 555489), CCR7 
BV421 (clone G043H7, BioLegend, catalog 353208), CD45RO BV650 
(clone UCHL1, BioLegend, catalog 304232), CD69 PE (clone FN50, 
BioLegend, catalog 310906), Vα24Jα18 efluor450 (clone 6B11, Invit-
rogen, catalog 48-5806-42), CD103-FITC (clone Ber-ACT8, BD Bio-
sciences — Pharmingen, catalog 550259), PLZF-APC (clone 6318100, 
R&D, catalog IC2944A), CD161-BV711 (clone DX12, BD Bioscienc-
es, catalog 563865), IL-18Rα–PE (clone H44, BioLegend, catalog 
313808), PD-1 BV605 (clone EH12.2H7, BioLegend, catalog 329924), 
IFN-γ–FITC (clone 25723.11, BD Biosciences, catalog 340449), IFN-γ–
BV650 (clone 4S.B3, BD Biosciences, catalog 563416), TNF-α–PE Cy7 
(clone MAB11, BD Biosciences — Pharmingen, catalog 557647), IL-2 
(clone 5344.11, BD, catalog 340448), IL-8 BV421 (clone G265-8, BD 
Biosciences, catalog 563310), IL-10 Pe (clone JES3-19F1, BD Biosci-
ences, catalog 562035), IL-4 PeCy7 (clone 8D4-8, BD Biosciences, 
catalog 560672), IL-17A Pe (clone eBIO64DEC17, eBioscience, cata-
log 12-7179-42), CD45 APC (clone HI30, Tonbo, catalog 20-0459), 
CD14 BV605 (clone M5E2, BD Biosciences — Pharmingen, catalog 
564054), CD11c BB515 (clone B-ly6, BD Biosciences — Pharmingen, 
catalog 564491), HLA-DR APC-R700 (clone G46-6, BD Bioscienc-
es, catalog 565128), CD3 BV510 (clone HIT3α, BD Biosciences, cat-
alog 564713), CD19 BV510 (clone SJ25C1, BD Biosciences, catalog 
562947), CD56 BV510 (clone NCAM16.2, BD Biosciences, catalog 
563041), CD68 PE Cy7 (clone FA-11, BioLegend, catalog 137016), 
CD163 BV711 (clone GHI/61, BioLegend, catalog 333630), CD209 
PerCP Cy 5.5 (clone DCN46, BD Biosciences — Pharmingen, cata-
log 558263), LLT1 PE (clone 402659 R&D, catalog FAB3480P), and 
Nur77-PE (clone 12.14, eBioscience, catalog 12-5965-80). TCR-β rep-
ertoire profiling was performed by staining with the IOTest Beta Mark 
TCR V β Repertoire Kit (Beckman Coulter). All cells were stained with 
Aqua LIVE/DEAD Fixable Dead Cell Stain Kit (Invitrogen) to exclude 
dead cells from analysis. All data were acquired with an LSR/Fortessa 
Dual SORP flow cytometer (BD Biosciences) and analyzed with Flow-
Jo V10.0.8 (TreeStar) software.
Immunohistochemistry. Intestinal segments were fixed in 4% 
paraformaldehyde for 10 minutes and dehydrated in a sucrose gra-
dient prior to embedding in OCT. Embedded tissues were frozen on 
dry ice and stored at –80°C, and 10 μm thin cryosections were mount-
ed on frosted charged slides. Histological work, imaging, and image 
processing were performed by the Gladstone Institutes’ Histology and 
Light Microscopy Core. Slides were fixed in acetone for 5 minutes at 
–20°C, rehydrated in PBS for 10 minutes, rinsed in 0.05% PBS-Tween, 
and permeabilized in 0.1% PBS–Triton X-100 for 15 minutes at room 
temperature (RT). Slides were blocked using 1% BSA, 0.1% fish skin 
gelatin, 0.5% Triton X-100,and 0.05% Na-Azide in PBS for 2 hours 
ty of memory CD8+ T cells within nonlymphoid tissue are TRM, 
whereas secondary lymphoid organs contain mostly recirculating 
(TEM and TCM) subsets (75). In humans, defining the relation-
ship between circulating and memory T cells within different 
anatomic compartments remains a daunting challenge. Our data 
suggest that PLZF+CD4+ T cells may play a role in fetal immune 
activation and that disturbances in this population may contribute 
to diverse inflammatory pathologies that occur during the perina-
tal period. A recent longitudinal, systems-level immune analysis 
in newborns revealed that human immune cells reached adult-like 
phenotypes by 3 months of age, with the notable exception of T 
cells (76). Whether intestinal PLZF+CD4+ T cells gradually disap-
pear in healthy infants and whether early gut dysbiosis results in 
the persistence of these T cells will be explored in futures studies.
These data add to our knowledge of the composition and func-
tion of the protective arm of the fetal adaptive immune system, in 
particular to the establishment of tissue-localized responses. The 
presence of a sizeable fraction of PLZF+CD4+ T cells with Th1 effec-
tor potential offers a more nuanced appreciation of human fetal 
immune development and highlights the unique challenges faced 
by the developing immune system as it transitions from a program 
of tolerance to one of protective immunity during the last trimes-
ter of pregnancy. We have identified a mechanism of fetal-specific 
immune suppression through CD161 blockade, which likely works 
in concert with multiple other regulatory mechanisms to actively 
promote immune suppression in utero (4, 77, 78) and could be har-
nessed therapeutically for the prevention or treatment of fetal and 
neonatal inflammatory pathologies. Beyond the perinatal period, 
expanding our knowledge of human fetal immune development 
and function is of utmost importance to our understanding of the 
early origins of predisposition to adult inflammatory diseases.
Methods
Cell isolation. PBMCs from adult and cord blood were isolated by 
Ficoll-Histopaque (Sigma-Aldrich) gradient centrifugation and cryo-
preserved in freezing medium (90% FBS + 10% DMSO; ATCC) and 
analyzed in batches. Fetal and adult organs were collected into cold 
RPMI with 10% FCS, 10 mM HEPES, penicillin, streptomycin, 0.1 
mM 2-β-mercaptoethanol, 2 mM l-glutamine, and nonessential ami-
no acids (cgRPMI medium), transported on ice, and processed within 
2 hours of collection. The SI and colon were dissected from the mes-
entery, opened longitudinally, and cut into 1 cm sections. Mucus was 
removed with 3 washes in 1 mM DTT in PBS for 10 minutes. The epi-
thelial layer was removed with 3 washes in 1 mM EDTA in PBS for 20 
minutes. The intestine, MLN, liver, lung, and spleen were minced into 
smaller pieces and digested with freshly prepared 3 mg/mL collage-
nase IV (Life Technologies) and 10 mg/mL DNAse (Roche) in cgRPMI 
for 30 minutes, and dissociated cells were filtered through a 70 μm 
strainer. Cells were separated in a 20%/40%/80% Percoll density gra-
dient at 400 g for 40 minutes. T cells were recovered at the 40%–80% 
interface, APCs were recovered at the 20%–40% interface, and all 
cells were washed twice in cgRPMI. All washes and incubations were 
performed in a shaking (200 rpm) water bath at 37°C. Thymocytes 
were isolated by gently pressing small pieces of thymus though a 70 
μm strainer. Viability was measured with Trypan Blue (Sigma Aldrich).
Antibodies and flow cytometry. Intestinal LP T cells were isolat-
ed by negative selection using the EasySep Human T Cell Isolation 
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the Nugen/Nextera XT Library Prep Kit (Illumina), and 15 samples (5 
donors, 3 T cell subsets) were sequenced on an Illumina HiSeq 4000 
by the Functional Genomics Core Facility at UCSF. The reads from 
the Illumina HiSeq sequencer in fastq format were verified for qual-
ity control using the fastqc software package. Reads were aligned to 
the human genome (hg38) and read counts aggregated by gene using 
the Ensembl GRCh38.78 annotation using STAR (79). Differential 
gene expression analysis was performed with the DESeq2, version 
1.16.1, package (80).
Statistics. Groups were compared with Prism, version 6, software 
(GraphPad). Data were analyzed using Wilcoxon’s test for paired 
nonparametric data, Mann-Whitney U test for unpaired nonpara-
metric data, and the Kruskal-Wallis with Dunn’s multiple compari-
son test for comparison of 3 or more groups. Box plot rectangles show 
first to third quartile, the line shows the median, and the whiskers 
represent minimum and maximum values, unless otherwise stated. 
Correlation analysis was measured by Spearman’s correlation coeffi-
cient. Bar plots represent the mean and the SEM. P < 0.05 was con-
sidered significant. Linear mixed effects (LME) modeling was used 
to evaluate significance in dose-response inhibition to CD161 anti-
body crosslinking. Principle component analysis and accompanying 
confidence intervals were performed using combined functions in 
the R packages stats, vegan, and ggplot2, and PERMANOVA anal-
ysis was used to assess the significance of the Euclidean distances 
between the groups. Heatmaps were generated using the R packag-
es heatmap and circlize. A coexpression analysis was performed for 
the differentially expressed (DE) genes using the Human Primary 
Cell Atlas (39). This atlas contains 713 microarray samples of a wide 
range of pure cell types and states. The complexity of the data set 
was reduced to the median gene expression per cell state (n = 157), 
and Spearman’s correlation coefficients were calculated for each pair 
of DE genes, revealing clusters of genes that are coexpressed in the 
same set of cell types. Gene clusters were analyzed for overlap with 
KEGG and GO biological processes gene sets using the Molecular 
Signatures Database (MSigDB) (81, 82). No statistical methods were 
used to predetermine sample size. The experiments were not ran-
domized, and the investigators were not blinded to allocation during 
experiments and outcome assessment.
Study approval. Human fetal tissues (15 to 23 weeks GA) were 
obtained from San Francisco General Hospital (San Francisco, Cal-
ifornia, USA) from terminations of pregnancy after maternal writ-
ten informed consent with approval from and under the guidelines 
of the UCSF Research Protection program. Samples were excluded 
in the cases of (a) known maternal infection, (b) intrauterine fetal 
demise, and/or (c) known or suspected chromosomal abnormali-
ty. Adult intestinal tissues were obtained after written informed 
consent from the UCSF Biospecimen Resources Program. Adult SI 
was obtained from routine resections during Whipple procedures, 
and adult colon was obtained during hemicolectomies and surgical 
resections. PBMCs derived from Trima residues from Trima Apher-
esis collection kits were obtained from healthy donors after written 
informed consent at the Blood Centers of the Pacific. Approval for 
healthy, term umbilical cord blood collection was obtained from 
the University of Texas MD Anderson Cancer Center (Houston, 
Texas, USA) with written informed consent between January 2017 
and June 2018. Eligibility criteria for term infant control samples 
included healthy infants delivered at more than 37 weeks GA; sam-
and stained with purified anti-CD3 (clone Hit3a; BD Biosciences — 
Pharmingen, catalog 555336) and anti-PLZF (clone NBPI-80894, 
Novus Biologicals, catalog NBPI-80894) overnight at 4°C, followed 
by anti-CD4–eFluor 570 (N1UG0, Thermo Fisher, catalog 41-2444-
82) at RT for 3 hours. Slides were incubated with secondary antibody 
goat anti-mouse-DyLight 488 (Thermo Fisher, catalog 35502) and 
goat anti-rabbit 633 (Thermo Fisher, catalog A-21070) for 1 hour at 
RT, stained with DAPI (Invitrogen) for 10 minutes at RT, and mount-
ed with Fluormount-G (EMS). Images were captured with a Zeiss Cell 
Observer Spinning Disk microscope (Carl Zeiss Microscopy) equipped 
with 405 nm, 488 nm, 561 nm, 633 nm lasers, a prime 95b sCMOS 
camera (Photometrics), and Zeiss Zen imaging software.
T cell stimulation and CD161 inhibition. For detection of basal 
cytokine potential, single cell suspensions from various tissues were 
cultured directly ex vivo in a 96-well U-bottom plate in cgRPMI and 
stimulated with 50 ng/ml PMA (Santa Cruz Biotechnology Inc., cat-
alog SC-3576) and 5 μg/ml ionomycin (Sigma-Aldrich) in the pres-
ence of Brefeldin A (Sigma-Aldrich, catalog B7651-5MG) for 3 hours 
at 37°C in 4% O2 to mimic intrauterine hypoxia. For Nur77 induc-
tion, T cells were cultured at 500 K/well in 96-well plates and stim-
ulated with plate-bound anti-CD3 (clone HIT3a, BioLegend, catalog 
300313) at 1 μg/ml and soluble anti-CD28 (CD28.2) at 2 μg/ml for 4 
hours at 37°C in 4% O2. For cytokine production, T cells were cultured 
at 250 K/well in 96-well plates and stimulated with plate-bound 
anti-CD3 at 1 μg/ml and soluble anti-CD28 (CD28.2, Invitrogen, cat-
alog MA1-20792) at 2 μg/ml, or cells were activated with 50 μg IL- 12 
(PeproTech, catalog 200-12) and IL-18 (R&D Systems, catalog 9124-
IL-050) at 50 ng/mL for 16–20 hours at 37°C in 4% O2, and Brefeldin 
A was added for the last 4 hours. After stimulation, cells were stained 
for intracellular cytokine production as described above. For the 
inhibition assays, T cells were first incubated with anti-CD161 biotin 
mAbs (clone HP3G10, BioLegend, catalog 339932, or clone 191B8, 
Miltenyi Biotec, catalog 130-092-906) or isotype-biotin controls 
IgG1 (MOPC-21, BioLegend, catalog 400104) and IgG2a (MOPC-
173, BioLegend, catalog 400204) for 15 minutes, washed, and cross-
linked with Anti-Biotin Cocktail (STEMCELL Technologies) at 1:50 
dilution during stimulation with anti-CD3/anti-CD28 or cytokines 
as described above. For glucocorticoid-induced apoptosis assays, T 
cells were incubated in the presence of dexamethasone (Sigma-Al-
drich) (10–6–10–9 M) or ethanol vehicle control alone or stimulated 
with Immunocult Human CD3/CD28/CD2 T cell activator beads 
(STEMCELL Technologies, catalog 10990) for 36 hours. T cells were 
then stained for annexin V using the Annexin V Apoptosis Detection 
Kit FITC (eBioscience, catalog 88-8005-74) according to the man-
ufacturer’s instructions, followed by intracellular staining for PLZF 
and/or intracellular cytokine production as above.
T cell isolation and RNA extraction for RNA-Seq. PLZF+ and PLZF–
CD4+ TCR-β+ T cells were sorted using FACSAria2 SORP (BD Biosci-
ences). T cells were isolated as described above from the intestine 
of 5 individual samples. MAIT cells were pooled from the intestine 
and MLN for RNA-Seq as outlined in Supplemental Figure 3A, and 
104 cells were collected per subset for each sample. Postsort purity 
was determined by flow cytometry following intracellular staining 
for PLZF as above and was more than 92% for PLZF– T cells and 
MAIT cells and more than 87% for PLZF+ T cells. RNA was extract-
ed and purified with the Dynabeads mRNA DIRECT Purification Kit 
(Thermo Fisher Scientific). mRNA libraries were constructed using 
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